Cantor Fitzgerald set a $137.00 target price on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in a research note released on Thursday morning. The firm currently has a hold rating on the medical equipment provider’s stock.

Several other brokerages also recently commented on ZBH. Morgan Stanley increased their price objective on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an overweight rating in a research note on Monday, July 17th. Stifel Nicolaus reissued a hold rating and issued a $125.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Piper Jaffray Companies reissued a buy rating and issued a $141.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Canaccord Genuity reissued a buy rating and issued a $141.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Finally, Royal Bank Of Canada reissued an outperform rating and issued a $140.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $137.76.

Zimmer Biomet Holdings (NYSE ZBH) opened at 123.78 on Thursday. The firm has a 50-day moving average price of $127.89 and a 200-day moving average price of $121.20. The company has a market capitalization of $24.98 billion, a P/E ratio of 35.25 and a beta of 1.21. Zimmer Biomet Holdings has a 1-year low of $95.63 and a 1-year high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the consensus estimate of $2.10 by $0.02. The company had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period last year, the company earned $2.02 earnings per share. On average, analysts forecast that Zimmer Biomet Holdings will post $8.36 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Given a $137.00 Price Target at Cantor Fitzgerald” was posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-zbh-given-a-137-00-price-target-at-cantor-fitzgerald/1463440.html.

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 28th. Shareholders of record on Friday, June 23rd were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.78%. The ex-dividend date of this dividend was Wednesday, June 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is 27.59%.

In other news, VP Chad F. Phipps sold 6,200 shares of the firm’s stock in a transaction on Friday, May 5th. The stock was sold at an average price of $116.76, for a total value of $723,912.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the company. Enterprise Financial Services Corp increased its stake in Zimmer Biomet Holdings by 0.3% in the second quarter. Enterprise Financial Services Corp now owns 2,646 shares of the medical equipment provider’s stock worth $340,000 after buying an additional 9 shares during the last quarter. Parsec Financial Management Inc. increased its stake in Zimmer Biomet Holdings by 3.8% in the second quarter. Parsec Financial Management Inc. now owns 52,117 shares of the medical equipment provider’s stock worth $6,692,000 after buying an additional 1,923 shares during the last quarter. River Wealth Advisors LLC increased its stake in Zimmer Biomet Holdings by 1.5% in the second quarter. River Wealth Advisors LLC now owns 15,091 shares of the medical equipment provider’s stock worth $1,938,000 after buying an additional 216 shares during the last quarter. Cadence Bank NA increased its stake in Zimmer Biomet Holdings by 3.0% in the second quarter. Cadence Bank NA now owns 1,687 shares of the medical equipment provider’s stock worth $217,000 after buying an additional 49 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its stake in Zimmer Biomet Holdings by 9.7% in the second quarter. Daiwa Securities Group Inc. now owns 7,350 shares of the medical equipment provider’s stock worth $944,000 after buying an additional 650 shares during the last quarter. Institutional investors own 84.37% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.